Ki-ras mutations are an early event and correlate with tumor stage in transplacentally-induced murine lung tumors

Carcinogenesis

Volumn 18, Issue 6, 1997, Pages 1163-1168

  Leone Kabler, Sandra ^a   Wessner, Lisa L ^b,c   McEntee, Michael F ^b   D'Agostino Jr , Ralph B ^a   Miller, Mark Steven ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; RAS PROTEIN;

ADENOCARCINOMA; ADENOMA; ANIMAL CELL; ARTICLE; CANCER STAGING; CELL DIFFERENTIATION; CODON; CONTROLLED STUDY; GENE AMPLIFICATION; GENE LOCUS; GENE MUTATION; HYPERPLASIA; LUNG CARCINOGENESIS; LUNG TUMOR; MOUSE; NONHUMAN; ONCOGENE K RAS; PHENOTYPE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANIMALS; BLOTTING, NORTHERN; CARCINOGENS; CYTOCHROME P-450 CYP1A1; FEMALE; GENES, RAS; LUNG NEOPLASMS; MALE; MATERNAL-FETAL EXCHANGE; METHYLCHOLANTHRENE; MICE; MICE, INBRED DBA; MUTATION; NEOPLASM STAGING; PHENOTYPE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RNA, NEOPLASM; SEX FACTORS; SIGNAL TRANSDUCTION;

EID: 0031417559     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/18.6.1163     Document Type: Article

References (50)

1. Reynolds, S.H., Wiest, J.S., Devereux, T.R., Anderson, M.W. and You, M. (1992) Protooncogene activation in spontaneously occurring and chemically induced rodent and human lung tumors. In Klein-Szanto, A.J.P. Anderson, M.W., Barrett, J.C. and Slaga, T.J. (eds) Comparative Molecular Carcinogenesis, Wiley-Liss, Inc., New York, pp. 303-320.
2. Conti, C.J. (1992) Mutations of genes of the ras family in human and experimental tumors. In Klein-Szanto, A.J.P., Anderson, M.W., Barrett, J.C. and Slaga, T.J. (eds) Comparative Molecular Carcinogenesis. Wiley-Liss, Inc., New York, pp. 357-378.
3. Carbone, D.P. and Minna, J.D. (1992) The molecular genetics of lung cancer. In Stollerman, G.H., LaMont, J.T., Leonard, J.J. and Siperstein, M.D. (eds) Advances in Internal Medicine, Mosby Year Book, Inc., St Louis, vol. 37, pp. 153-171.
4. Nakano, H., Yamamoto, F., Neville, C., Evans, D., Mizuno, T. and Perucho, M. (1984) Isolation of transforming sequences of two human lung carcinomas: structural and functional analysis of the activated c-K-ras oncogenes. Proc. Natl Acad. Sci. USA, 81, 71-75.
5. Rodenhuis, S., van de Wetering, M.L., Mooi, W.J., Evers, S.G., van Zandwijk, N. and Bos, J.L. (1987) Mutational activation of the K-ras oncogene: A possible pathogenetic factor in adenocarcinoma of the lung. New Engl. J. Med., 317, 929-935.
6. Rodenhuis, S., Slebos, R.J.C., Boot, A.J.M., Evers, S.G., Mooi, W.J., Wagenaar, S.Sc., van Bodegom, P.Ch. and Bos, J.L. (1988) Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res., 48, 5738-5741.
7. Mitsudomi, T., Viallet, J., Mulshine, J.L., Linnoila, R.I., Minna, J.D. and Gazdar, A.F. (1991) Mutations of ras genes distinguish a subset of non-small cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene, 6, 1353-1362.
8. Slebos, R.J.C., Hruban, R.H., Dalesio, O., Mooi, W.J., Offerhaus, G.J.A. and Rodenhuis, S. (1991) Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J. Natl Cancer Inst., 83, 1024-1027.
9. Mills, N.E., Fishman, C.L., Rom, W.N., Dubin, N. and Jacobson, D.R. (1995) Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res., 55, 1444-1447.
10. Miller, M.S. (1994) Transplacental lung carcinogenesis: a pharmacogenetic mouse model for the modulatory role of cytochrome P450 1A1 on lung cancer. Chem. Res. Toxicol., 7, 471-481.
11. Bunin, G.R., Kramer, S., Marrero, O. and Meadows, A.T. (1987) Gestational risk factors for Wilms' tumor: results of a case-control study. Cancer Res., 47, 2972-2977.
12. Stjernfeldt, M., Berglund, K., Lindsten, J. and Ludvigsson, J. (1986) Maternal smoking during pregnancy and risk of childhood cancer. Lancet, 1, 1350-1352.
13. John, E.M., Savitz, D.A. and Sandler, D.P. (1991) Prenatal exposure to parents' smoking and childhood cancer. Am. J. Epid., 133, 123-132.
14. Sandler, D.P. Everson, R.B., Wilcox, A.J. and Browder, J.P. (1985) Cancer risk in adulthood from early life exposure to parents' smoking. Am. J. Public Health, 75, 487-492.
15. Hatch, M.C., Warburton, D. and Santella, R.M. (1990) Polycyclic aromatic hydrocarbon-DNA adducts in spontaneously aborted fetal tissue. Carcinogenesis, 11, 1673-1675.
16. Hansen, C., Sørensen, L.D., Asmussen, I. and Autrup, H. (1992) Transplacental exposure to tobacco smoke in human-adduct formation in placenta and umbilical cord blood vessels. Teratogen., Carcinogen. Mutagen., 12, 51-60.
17. Coghlin, J., Gann, P.H., Hammond, S.K., Skipper, P.L., Taghizadeh, K., Paul, M. and Tannenbaum, S.R. (1991) 4-Aminobiphenyl hemoglobin adducts in fetuses exposed to the tobacco smoke carcinogen in utero. J. Natl Cancer Inst., 83, 274-280.
18. Manchester, D.K., Weston, A., Choi, J.-S., Trivers, G.E., Fennessey, P.V., Quintana, E., Farmer, P.B., Mann, D.L. and Harris, C.C. (1988) Detection of benzo[a]pyrene diol epoxide-DNA adducts in human placenta. Proc. Natl Acad. Sci. USA, 85, 9243-9247.
19. Manchester, D.K., Bowman, E.D., Parker, N.B., Caporaso, N.E. and Weston, A. (1992) Determinants of polycyclic aromatic hydrocarbon-DNA adducts in human placenta. Cancer Res., 52, 1499-1503.
20. Whyatt, R.M., Garte, S.J., Cosma, G. et al. (1995) CYP1A1 messenger RNA levels in placental tissue as a biomarker of environmental exposure. Cancer Epidemiol., Biomark. Prev., 4, 147-153.
21. Whyatt, R.M., Santella, R., Garte, S.J., Ottman, R., Gladek-Yarborough, A., Young, T., Jedrychowski, W., Cosma, G. and Perera, F.P. (1995) Effects of environmental exposures on DNA damage in women and the developing fetus and its modulation by genetic/metabolic factors. Proc. Am. Assoc. Cancer Res., 36, 1690.
22. Anderson, L.M., Jones, A.B., Riggs, C.W. and Ohshima, M. (1985) Fetal mouse susceptibility to transplacental lung and liver carcinogenesis by 3-methylcholanthrene: positive correlation with responsiveness to inducers of aromatic hydrocarbon metabolism. Carcinogenesis, 6, 1389-1393.
23. Miller, M.S., Jones, A.B., Chauhan, D.P., Park, S.S. and Anderson, L.M. (1989) Differential induction of fetal mouse liver and lung cytochromes P-450 by β-naphthoflavone and 3-methylcholanthrene. Carcinogenesis, 10, 875-883.
24. Miller, M.S., Jones, A.B., Chauhan, D.P. and Anderson, L.M. (1990) Role of the maternal environment in determining susceptibility to transplacentally induced chemical carcinogenesis in mouse fetuses. Carcinogenesis, 11, 1979-1984.
25. Miller, M.S., Jones, A.B. and Anderson, L.M. (1990) The formation of 3-methylcholanthrene-initiated lung tumors correlates with induction of cytochrome CYPIA1 by the carcinogen in fetal but not adult mice. Toxicol. Appl. Pharmacol., 104, 235-245.
26. Wessner, L.L., Fan, M., Schaeffer, D.O., McEntee, M.F. and Miller, M.S. (1996) Mouse lung tumors exhibit specific Ki-ras mutations following transplacental exposure to 3-methylcholanthrene. Carcinogenesis, 17, 1519-1526.
27. Rehm, S., Ward, J.M., Have-Opbroek, A.A.W.T., Anderson, L.M., Singh, G., Katyal, S.L. and Rice, R.M. (1988) Mouse papillary lung tumors transplacentally induced by N-nitrosoethylurea: evidence for alveolar type II cell origin by comparative light microscopic, ultrastructural and immunohistochemical studies. Cancer Res., 48, 148-160.
28. Faccini, J.M., Abbott, D.P. and Paulus, G.J.J. (1990) Mouse Histopathology: a Glossary for Use in Toxicity and Carcinogenicity Studies. Elsevier Scientific Publications Co., New York, pp. 48-62.
29. Wright, D.K. and Manos, M.M. (1990) Sample preparation from paraffin-embedded tissues. In Innis, M.A., Gelfand, D.H., Sninsky, J.J. and White, T.J. (eds) PCR Protocols: A Guide to Methods and Applications. Academic Press, Inc., San Diego, pp. 153-158
30. Devereux, T.R. Anderson, M.W. and Belinsky, S.A. (1991) Role of ras proto-oncogene activity in the formation of spontaneous and nitrosamine-induced lung tumors in the resistant C3H mouse. Carcinogenesis, 12, 299-303.
31. Saiki, R.K., Gelfand, D.H., Stoffel S., Scharf, S.J., Higuchi, R., Horn, G.T., Mullis, K.B. and Erlich, H.A. (1988) Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science, 239, 487-491.
32. Miller, M.S., Baxter, J.L., Moore, J.W., Lewis, J.D. and Schuller, H.M. (1994) Molecular characterization of neuroendocrine lung tumors induced in hamsters by treatment with nitrosamines and hyperoxia. Int. J. Oncol., 4, 5-12.
33. Sanger, F., Nicklen, S. and Coulson, A.R. (1977) DNA sequencing with chain-terminating inhibitors. Proc. Natl Acad. Sci. USA, 74, 5463-5467.
34. MacDonald, R.J., Swift, G.H., Przybyla, A.E. and Chirgwin, J.M. (1987) Isolation of RNA using guanidinium salts. Methods Enzymol., 152, 219-227.
35. Thomas, P.S. (1983) Hybridization of denatured RNA transferred or dotted to nitrocellulose paper. Methods Enzymol., 100, 255-266.
36. Angel, P., Allegretto, E.A., Okino, S.T., Hattori, K., Boyle, W.J., Hunter, T. and Karin, M. (1988) Oncogene jun encodes a sequence-specific trans-activator similar to AP-1. Nature, 332, 166-171.
37. Stanton, L.W., Rosemary, W. and Marcu, K.B. (1983) Translocation, breakage and truncated transcripts of c-myc oncogene in murine plasmacytomas. Nature, 303, 401-406.
38. Curran, T., Peters, G., van Beveren, C., Teich, N.M. and Verma, I.M. (1982) FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA. J. Virol., 44, 674-682.
39. McCoy, M.S. and Weinberg, R.A. (1986) A human Ki-ras oncogene encodes two transforming p21 proteins. Mol. Cell Biol., 6, 1326-1328.
40. Xiong, Y., Connolly, T., Futcher, B. and Beach, D. (1991) Human D-type cyclin. Cell, 65, 691-699.
41. Koff, A., Cross, F., Fisher, A., Schumacher, J., Legueliec, K., Phillippe, M. and Roberts, J.M. (1991) Human cyclin E a new cyclin that interacts with two members of the CDC2 gene family. Cell, 66, 1217-1228.
42. Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K. and Elledge, S.J. (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805-816.
43. Tso, J.Y., Sun, X-H., Kao, T., Reece, K.S. and Wu, R. (1985) Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. Nucleic Acids Res., 13, 2485-2502.
44. Massey, T.E., Devereux, T.R., Maronpot, R.R., Foley, J.E. and Anderson, M.W. (1995) High frequency of K-ras mutations in spontaneous and vinyl chloride-induced lung tumors of relatively resistant B6C3F1 (C57BL/ 6JxBALB/cJ) mice. Carcinogenesis, 16, 1065-1069.
45. Rosell, R., Li, S., Skacel, Z. et al. (1993) Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene, 8, 2407-2412.
46. Keohavong, P., DeMichele, M.A.A., Melacrinos, A.C., Landreneau, R.J., Weyant, R.J. and Siegfried, J.M. (1996) Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin. Cancer Res., 2, 411-418.
47. Li, Z-H., Zheng, J., Weiss, L.M. and Shibata, D. (1994) c-K-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am J. Path., 144, 303-309.
48. Westra, W.H., Baas, I.O., Hruban, R.H., Askin, F.B., Wilson, K., Offerhaus, G.J.A. and Slebos, R.J.C. (1996) K-ras activation in atypical alveolar hyperplasias of the human lung. Cancer Res., 56, 2224-2228.
49. Sugio, K., Kishimoto, Y., Virmani, A.K., Hung, J.Y. and Gazdar, A.F. (1994) K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res., 54, 5811-5815.
50. Miller, M.S., Juchau, M.R., Guengerich, F.P., Nebert, D.W. and Raucy, J.L. (1996) Drug metabolic enzymes in developmental toxicology. Fund. App. Tox., 34, 165-175.